Robin K Dore
Overview
Explore the profile of Robin K Dore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dore R, Antonova J, Burudpakdee C, Chang L, Gorritz M, Genovese M
ACR Open Rheumatol
. 2021 Nov;
4(6):473-482.
PMID: 34792867
Objective: Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and...
2.
Leder B, Zapalowski C, Hu M, Hattersley G, Lane N, Singer A, et al.
J Bone Miner Res
. 2019 Aug;
34(12):2213-2219.
PMID: 31411768
In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the...
3.
Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M, et al.
J Clin Endocrinol Metab
. 2018 May;
103(8):2949-2957.
PMID: 29800372
Purpose: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods:...
4.
Dore R
Adolesc Health Med Ther
. 2014 Apr;
5:35-48.
PMID: 24729739
Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory diseases affecting approximately 300,000 children and adolescents in the United States of unknown cause. It can affect children from the...
5.
6.
Dore R
Patient Prefer Adherence
. 2013 May;
7:435-46.
PMID: 23717037
Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of...
7.
Dore R
Curr Osteoporos Rep
. 2011 Nov;
10(1):16-21.
PMID: 22086442
Osteoporosis and fractures that occur as a result of this condition pose a huge public health problem to society and result in morbidity and mortality to individuals. Because osteoporosis is...
8.
Dore R
Rheum Dis Clin North Am
. 2011 Oct;
37(3):433-52, vi-vii.
PMID: 22023901
Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-κB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts. It was approved...
9.
Dore R
Cleve Clin J Med
. 2010 Aug;
77(8):529-36.
PMID: 20682515
When prescribing glucocorticoids for long-term treatment, physicians should take steps to prevent osteoporosis, a common and serious side effect of these drugs.
10.
Dore R, Cohen S, Lane N, Palmer W, Shergy W, Zhou L, et al.
Ann Rheum Dis
. 2009 Sep;
69(5):872-5.
PMID: 19734132
Objectives: To report results of subgroup analyses of bone mineral density (BMD) and bone turnover markers from a randomised, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor,...